Schedule 13D ownership disclosure

NOVABRIDGE BIOSCIENCES

Ordinary shares, par value US$0.0001 per share · CUSIP: 44975P103

Event date: 2025-08-05

Filing-level shares
42,524,716
Percent of class
16.1%
  • Everest Medicines LimitedReported CIK 0001783937

    Shares: 42,524,716 · Class: 16.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-102964
Form type
SCHEDULE 13D
Filer
Everest Medicines Ltd
CIK
CIK 1783937
Filed
Aug 05, 2025
Reporting period
Aug 05, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub